MedPath

Dual-center retrospective study on the efficacy and safety of neoadjuvant therapy in the patients with resectable pancreatic cancer

Not Applicable
Recruiting
Conditions
pancreatic cancer
Registration Number
JPRN-UMIN000052876
Lead Sponsor
School of Medicine, Wakayama Medical School
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
550
Inclusion Criteria

Not provided

Exclusion Criteria

1. diagnosis of borderline or unresectable pancreatic cancer according to NCCN guideline (Ver.2. 2021) 2. conversion surgery in the patients with unresectable pancreatic cancer

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Comparison of overall survival between upfront surgery and neoadjuvant therapy in the patients with resectable pancreatic cancer
Secondary Outcome Measures
NameTimeMethod
1. detection of prognostic factor in the patients with resectable pancreatic cancer 2. comparison of recurrence free survival between upfront surgery and neoadjuvant therapy 3. comparison of surgical outcome between upfront surgery and neoadjuvant therapy 4. comparison of morbidity and induction of the adjuvant therapy between upfront surgery and neoadjuvant therapy 5. detection of the unresectable factor in the patients received neoadjuvanvt therapy with resectable pancreatic cancer
© Copyright 2025. All Rights Reserved by MedPath